Blueprint Medicines (NASDAQ:BPMC) Stock Rating Reaffirmed by HC Wainwright
Blueprint Medicines (NASDAQ:BPMC)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday, AnalystRatings.com reports.
Several other analysts have also recently commented on BPMC. BMO Capital Markets raised their price target on shares of Blueprint Medicines from $75.00 to $111.00 and gave the company an “outperform” rating in a report on Monday, June 8th. SVB Leerink lifted their target price on Blueprint Medicines from $106.00 to $107.00 and gave the company an “outperform” rating in a research note on Monday, July 27th. Deutsche Bank raised their price target on Blueprint Medicines from $85.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. ValuEngine cut Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Friday, May 1st. Finally, Raymond James raised their target price on shares of Blueprint Medicines from $95.00 to $106.00 and gave the company a “strong-buy” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $96.15.
NASDAQ BPMC opened at $73.18 on Friday. The stock’s 50 day simple moving average is $76.68 and its 200 day simple moving average is $67.22. The company has a debt-to-equity ratio of 0.13, a current ratio of 7.17 and a quick ratio of 7.14. Blueprint Medicines has a one year low of $43.29 and a one year high of $101.76. The firm has a market cap of $3.97 billion, a PE ratio of -9.54 and a beta of 1.09.
In other news, Director Nicholas Lydon sold 26,007 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $80.45, for a total transaction of $2,092,263.15. Following the completion of the sale, the director now owns 48,340 shares of the company’s stock, valued at $3,888,953. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Debra Durso-Bumpus sold 2,500 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $75.18, for a total transaction of $187,950.00. Following the completion of the sale, the insider now directly owns 22,005 shares in the company, valued at $1,654,335.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,349 shares of company stock valued at $5,001,908. Insiders own 3.81% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. Bourgeon Capital Management LLC bought a new stake in Blueprint Medicines in the 1st quarter valued at approximately $29,000. Ameritas Investment Partners Inc. grew its holdings in shares of Blueprint Medicines by 12.1% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,785 shares of the biotechnology company’s stock valued at $280,000 after acquiring an additional 518 shares in the last quarter. Advisor Group Holdings Inc. bought a new stake in Blueprint Medicines during the first quarter worth about $32,000. Strs Ohio boosted its position in Blueprint Medicines by 7.9% during the second quarter. Strs Ohio now owns 8,200 shares of the biotechnology company’s stock valued at $639,000 after purchasing an additional 600 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Blueprint Medicines by 23.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,600 shares of the biotechnology company’s stock valued at $211,000 after purchasing an additional 694 shares in the last quarter. Institutional investors and hedge funds own 97.96% of the company’s stock.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Further Reading: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.